Pfizer And J&J Settle Remicade Antitrust Litigation
Long-Running Case Over Infliximab Biosimilars Resolved On Confidential Terms
Pfizer and Johnson & Johnson have settled long-running US antitrust litigation over claims that contracts and deals for the Remicade brand were set up to dampen competition from infliximab biosimilars.
